BioNTech SE (BNTX)
BioNTech's cancer drug meets primary endpoint in Phase 2 trial
Reuters
Tue, Jul 30, 2024, 1:52 PM GMT+3
To confirm the signal, we need to close 3 sessions above 87.70$
Reuters
Tue, Jul 30, 2024, 1:52 PM GMT+3
To confirm the signal, we need to close 3 sessions above 87.70$
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.